Ivan O. Rosas, ERS 2022: Therapeutic Intervention for Interstitial Lung Disease in Patients with Rheumatoid Arthritis

TRAIL1 (ClinicalTrials.gov Identifier: NCT02808871) was a phase 2 randomised, double blind, placebo-controlled trial investigating pirfenidone in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We were delighted to speak to Professor Ivan O. Rosas (Baylor College of Medicine, Baylor Medicine McNair Campus, Houston, TX, USA) around the prognosis, choice of therapeutic intervention and the rationale for investigating antifibrotic agents in RA-ILD.

The abstract ‘Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.‘ (Abstract number: RCT2886) was presented at ERS 2022, 4–6 September, 2022.

Questions

1. Could you give us a brief overview of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)? (0:52)
2. How does the presence of ILD in RA influence the prognosis and choice of therapeutic intervention? (3:49)
3. What is the rationale for investigating antifibrotic agents in RA-ILD? (5:27)

Disclosures: Ivan O. Rosas discloses consulting for Genentech/Roche and receiving grant/ research support from Genentech/Roche.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ERS meeting 2022.

For further information, please view the published study article here and the design article here.